GEN News Highlights: Jan 19, 2012

JSR Teams with BIA to Develop and Market Purification Systems

(Page 1 of 1)

    JSR and BIA Separations entered a partnership that includes JSR taking a minor equity position on November 14, 2011. The companies started a joint global marketing and sales effort as well as collaborative R&D activities in the area of downstream purification to aid in the manufacture of vaccines, DNA, and antibody-based medicines.

    Through this arrangement JSR gains access to BIA Separations’ downstream purification technology. BIA’s technology will be combined with JSR’s Protein A media. BIA expects JSR’s global presence and expertise in the field of consistent high-quality volume manufacturing will help it successfully grow its business.

    JSR is headquartered in Tokyo and has factories and offices in Europe, the U.S., China, Taiwan, Korea, and Singapore. BIA Separations claims to be the only worldwide developer and manufacturer of CIM Convective Interaction Media®, short monolithic chromatographic columns optimized for the separation and purification of large biomolecules and viral particles on the laboratory and industrial scale.


Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll